Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

80.44 -1.06 (-1.30%)
Streaming Delayed Price Updated: 9:47 AM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,938
Open 80.98
Bid (Size) 80.41 (100)
Ask (Size) 80.56 (100)
Prev. Close 81.50
Today's Range 80.36 - 81.68
52wk Range 46.81 - 93.42
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗
Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review. 
Via The Motley Fool
Topics Earnings

Performance

YTD
+2.8%
+2.8%
1 Month
-4.3%
-4.3%
3 Month
+18.8%
+18.8%
6 Month
+18.5%
+18.5%
1 Year
+70.1%
+70.1%

More News

Read More
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Via The Motley Fool
BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup ↗
Via Chartmill
News headline image
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. ↗
Via The Motley Fool
News headline image
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. ↗
Via The Motley Fool
News headline image
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Via MarketBeat
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Via The Motley Fool
News headline image
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗
Via MarketBeat
News headline image
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 80.44
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 08/24/26 09:47 AM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 12.91B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.